m4344
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2020 (NCT04149145)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- ATR/ATRIPINHIBITOR
ATR/ATRIP inhibitor
- Serine-protein kinase ATRINHIBITOR
Serine-protein kinase ATR inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Nc1nn2cc(F)cnc2c1C(=O)Nc1cncc(F)c1N1CCC(C(=O)N2CCN(C3COC3)CC2)CC1- Mol. weight
- 541.56 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650286 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04655183 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2020 | Merck KGaA, Merck Serono |
| NCT04149145 | Phase 1 | Jan 1, 2020 | University of Alabama, Birmingham |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck KGaA | For profit | 1 | 0 | 1 | 2020 |
| Merck Serono | For profit | 1 | 1 | 1 | 2020 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 1 | 1 | 2020 |
3 organizations
Page 1 / 1